RESEARCH MONOGRAPH · KDC-MN-069

F-Phenibut (Fluorophenibut)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

50/100

Fluorinated phenibut analog with stronger GABA-B affinity, faster onset, and proportionally worse dependence math

F-phenibut (4-fluorophenibut, sometimes labeled fluorobut) is what happens when someone takes phenibut, adds a para-fluoro to the phenyl ring, and ships it without much new clinical work. The fluorine increases lipophilicity, accelerates BBB penetration, and bumps GABA-B affinity 2-5x depending on which binding study you trust. So everything phenibut does, F-phenibut does faster and at lower doses.

That sounds like an upgrade. It isn't. The dependence pharmacology scales with the receptor binding, which means tolerance develops faster, withdrawal hits harder, and the therapeutic window between "effect" and "problematic" is narrower than phenibut. We've seen multiple case reports of severe physical dependence developing within 2-3 weeks of regular F-phenibut use, which is faster than even phenibut.

Whats relevant for research: F-phenibut is a useful tool compound for studying GABA-B receptor pharmacology because the affinity is higher and the structural variation (fluorine substitution) is informative for SAR work. There's also some interesting biochemistry around how the fluorine affects metabolic stability and half-life relative to the parent compound, which is actually a real medicinal-chemistry teaching example.

What we like: it's a clean fluorinated analog with well-characterized SAR. The synthetic route from phenibut precursors is straightforward and HPLC purity is achievable for research-grade material.

What we dont like: basically everything about its non-research use. The way it gets sold as a "phenibut alternative" or stronger version totally ignores the dependence math. Russian clinical data is essentially nonexistent (this is a designer analog, not a registered drug like phenibut is in Latvia and a couple other countries), and the recreational supplement scene treats it casually in a way that's going to lead to more ER visits.

For pharmacology research, fine. For anything else, this is a compound where the risk profile genuinely exceeds the parent molecule and the literature behind it is much thinner.

Evidence: 25
Mechanism: 78
Reliability: 65
Safety: 25
Sourcing: 65
Value: 50
Signal: 55
Staying power: 35

Plain-language summary Intrigue 42 / 100

F-Phenibut is the fluorinated cousin of phenibut. It activates GABA-B receptors more potently than phenibut and has comparable dependence risk. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GABA-B agonist / fluoro-phenibut

A 4-fluoro-substituted phenibut analog with higher GABA-B affinity and lower dose requirement; sold as a research chemical with elevated dependence concerns.

Abstract

F-Phenibut (4-amino-3-(4-fluorophenyl)butanoic acid) is a fluorinated analog of phenibut with the addition of a para-fluoro substituent on the phenyl ring. The structural modification increases GABA-B receptor affinity and produces effective doses approximately 5- to 10-fold lower than phenibut. The compound is not approved in any jurisdiction and is sold as a research chemical. Mechanism parallels phenibut (GABA-B agonist) with the affinity increase. Dependence liability is at least as substantial as phenibut and may be greater on a dose-equivalent basis. Pharmacokinetics are not formally characterized in humans; rodent half-life is similar to phenibut. Reported research dose ranges in the literature are described in the source monograph. F-phenibut should be regarded as a higher-potency phenibut analog with all the dependence concerns of phenibut amplified by potency.

Mechanism of action

Higher-affinity GABA-B agonist than phenibut; same general pharmacology.

Reported research dose ranges

50 to 250 mg (reported research dose range) (research-grade).

References

Sparse formal literature; phenibut analog pharmacology papers.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-069

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

F-Phenibut (Fluorophenibut)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs